GAT

Nitraflax Hypermia & Testosterone Enhancing Tabs

Serving
3 Tablet(s)
Per container
60
Form
tablet
UPC
859613648815
DSLD
Formula hash
551682227a22
Brand context
Catalog
19
products
With avoid flag
7
products
FDA recalls
0
history
CAERS
1
reports
Avoid-flaggedObjective label signals
Flagged excipients
3
1 avoid · 2 caution
FDA recalls
0
no recall history
CAERS reports
1
FDA consumer events
Certifications
0
none recorded
1 avoid-level excipient · Every flag below links to the authority's published citation.

Supplement Facts

1 active ingredients
IngredientAmount% DV
Nitraflex Proprieceutical Blend
Proprietary Blend (Combination)other
4058 mg
Flagged excipients

3 flagged · authority citations

  • ● AVOIDTitanium Dioxide
    color

    Banned in EU food products effective 2022-08 (Commission Regulation (EU) 2022/63) following EFSA Panel opinion that a safe daily intake could not be established due to genotoxicity concerns. Still GRAS in the US under 21 CFR 73.575 but EU position is stricter.

  • ◐ CAUTIONFD&C Blue # 1
    color

    EU requires 'attention in children' warning per Commission Regulation 1333/2008 Annex III. Limited to specific food categories; capsule-shell use permitted with restrictions.

  • ◐ CAUTIONFD&C Yellow # 5
    color

    EU requires warning label 'may have an adverse effect on activity and attention in children' per Commission Regulation 1333/2008 Annex III (following Southampton study 2007). FDA requires specific label declaration (21 CFR 74.705).

FDA CAERS · adverse event context
1
consumer-submitted adverse event reports filed with the FDA CFSAN Adverse Event Reporting System mentioning this product or its brand.

CAERS reports are unverified consumer submissions — not adjudicated causality. Large well-known brands accumulate proportionally more reports simply due to broader use. About CAERS →

Other ingredients

Microcrystalline Cellulose · Dextrose · Sodium Starch Glycolate · Di-Calcium Phosphate · Magnesium Stearate · Stearic Acid